Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD is the lead sponsor of 6 current clinical trials in our Spain, Germany, France, Italy, Portugal and EU (CTIS) registers. 1 is recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Sacituzumab tirumotecan, Apalutamide and Apalutamide (Erleada). The most-studied condition is Metastatic Hormone-sensitive Prostate Cancer.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.
NCT07333066 · ClinicalTrials.gov ↗ · Metastatic Hormone-sensitive Prostate Cancer
Drugs: Apalutamide (Erleada), Docetaxel |
Phase 3 | Recruiting | 2026-06 | Germany, France, Spain, Italy, Portugal |
|
Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer
NCT07717099 · ClinicalTrials.gov ↗ · Metastatic Hormone-Sensitive Prostate Cance
Drugs: Darolutamide, Ra223 |
Phase 2 | Not yet open | 2026-09 | Spain |
|
Genitourinary Tumors With Sacituzumab Tirumotecan
NCT07716917 · ClinicalTrials.gov ↗ · Papillary Renal Carcinoma, Variant Histology Urothelial Carcinoma
Drug: Sacituzumab tirumotecan |
Phase 2 | Not yet open | 2026-10 | Spain |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System with Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Countries |
|---|---|---|---|
|
RINGQUEST: Exploring Understudied Genitourinary Tumors with Sacituzumab Tirumotecan; a Single-arm, Basket, Phase II Study.
2026-526048-10-00 · Neoplasms
Drug: Sacituzumab tirumotecan |
Phase 2 | Authorised | Spain |
|
Quantitative Unified Assessment of Novel Triplet therapy and Unconventional Maintenance with Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer: A Phase II Pilot Trial
2026-525550-11-00 · Male Urogenital Diseases
Drug: Xofigo |
Phase 2 | Authorised | Spain |
|
Phase III Randomized, International, Open-Label Clinical Trial of Treatment Intensification with Docetaxel plus Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment with Apalutamide: REINFORCE Trial
2025-524408-30-01 · CTIS ↗ · Neoplasms
Drug: Apalutamide |
Phase 3 | Ongoing | Spain, Germany, France + 2 more |
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Spain | 3 | 1 |
| Clinical trials in Germany | 1 | 1 |
| Clinical trials in France | 1 | 1 |
| Clinical trials in Italy | 1 | 1 |
| Clinical trials in Portugal | 1 | 1 |
| EU register (CTIS) | 3 | — |
A trial with sites in more than one country appears in each of those registers.
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD is the lead sponsor of 3 current trials on ClinicalTrials.gov in our Spain, Germany, France, Italy and Portugal registers, and 3 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of its 3 ClinicalTrials.gov trials is recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 7 drugs and biologicals as interventions. The most frequent are Sacituzumab tirumotecan (2), Apalutamide (1), Apalutamide (Erleada) (1), Darolutamide (1) and Docetaxel (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.